Proficio Capital Partners LLC Acquires 192,916 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Proficio Capital Partners LLC boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 25,929.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 193,660 shares of the biopharmaceutical company's stock after acquiring an additional 192,916 shares during the period. Proficio Capital Partners LLC owned about 0.15% of Alnylam Pharmaceuticals worth $45,570,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ALNY. Allworth Financial LP raised its holdings in Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock valued at $140,000 after acquiring an additional 38 shares in the last quarter. Huntington National Bank increased its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares during the period. IFP Advisors Inc raised its stake in shares of Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 47 shares in the last quarter. Nwam LLC lifted its stake in Alnylam Pharmaceuticals by 5.8% during the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock valued at $213,000 after purchasing an additional 50 shares during the last quarter. Finally, SYM FINANCIAL Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 6.2% in the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company's stock worth $260,000 after buying an additional 55 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares in the company, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,986 shares of company stock worth $20,397,849. Corporate insiders own 1.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Morgan Stanley raised their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Scotiabank decreased their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating for the company in a research note on Friday, February 14th. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. Finally, StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, January 9th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $304.26.

Alnylam Pharmaceuticals Stock Up 0.1 %

Shares of ALNY traded up $0.22 on Tuesday, reaching $243.75. The company's stock had a trading volume of 314,330 shares, compared to its average volume of 792,391. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The stock has a market capitalization of $31.56 billion, a PE ratio of -112.23 and a beta of 0.35. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a fifty day moving average of $254.35 and a 200-day moving average of $262.08.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.